Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021

  • ID: 4376242
  • Report
  • Region: Global
  • 78 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • Athersys
  • Caladrius
  • F Hoffmann-La Roche
  • Heron Therapeutics
  • Lupin
  • MORE
About Graft vs Host Disease (GVHD) Treatment

Graft-versus-host disease (GVHD) is an immune-mediated disease, which results from a multifaceted interaction amongst donor and recipient's adaptive immunity. GVHD is an induced indication and emerges post organ or tissue transplant. The probability of developing GVHD is higher in allogeneic transplant, a transplant where donor's organ/cell are used for transplantation compared with autologous transplant, a transplant where individual's cells have been used for transplant.

The analysts forecast the global graft vs host disease (GVHD) treatment market to grow at a CAGR of 7.15% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global graft vs host disease (GVHD) treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
  • Bristol-Myers Squibb
  • Novartis
  • Pfizer
  • F. Hoffmann-La Roche
Other prominent vendors
  • Abbott
  • AbbVie
  • Allergan
  • Anterogen
  • Astellas Pharma
  • Athersys
  • Baxter
  • Caladrius
  • Cellular Biomedicine Group
  • Cipla
  • Eisai
  • Eli Lilly
  • GlaxoSmithKline
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • Incyte Corporation
  • IPCA Laboratories
  • Kadmon Holdings
  • Lupin
  • Osiris Therapeutics
  • RedHill
  • Sanofi
  • Shire
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical
  • ViaCyte
Market drivers
  • Increased prevalence of cancer
  • For a full, detailed list, view the full report
Market challenges
  • Off-label use of drugs
  • For a full, detailed list, view the full report
Market trends
  • Inorganic growth strategies
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Athersys
  • Caladrius
  • F Hoffmann-La Roche
  • Heron Therapeutics
  • Lupin
  • MORE
PART 01:Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Market overview
  • Five forces analysis
PART 07: Pipeline landscape

PART 08: Market segmentation by disease type
  • Acute GVHD
PART 09: Geographical segmentation
  • GVHD treatment market in Americas
  • GVHD treatment market in EMEA
  • GVHD treatment market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Market challenges
PART 12: Market trends
  • Inorganic growth strategies
  • Newer applications of bone marrow transplant
  • Growing focus toward the use of biologics
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Mechanism of GVHD
Exhibit 02: Global GVHD treatment market growth promoters
Exhibit 03: Major acute GVHD symptoms
Exhibit 04: Major chronic GVHD symptoms
Exhibit 05: Global GVHD treatment market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis in global GVHD treatment market
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline molecules as per vendors
Exhibit 09: Key clinical trials
Exhibit 10: Segmentation of global GVHD treatment market by disease type 2016
Exhibit 11: Symptoms in acute GVHD
Exhibit 12: Global acute GVHD treatment market 2016-2021 ($ millions)
Exhibit 13: Symptoms in chronic GVHD
Exhibit 14: Global chronic GVHD treatment market 2016-2021 ($ millions)
Exhibit 15: Segmentation of global GVHD treatment market by geography 2016 and 2021
Exhibit 16: Segmentation of global GVHD treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 17: Market scenario in Americas
Exhibit 18: GVHD treatment market in Americas 2016-2021 ($ millions)
Exhibit 19: Market scenario in EMEA
Exhibit 20: GVHD treatment market in EMEA 2016-2021 ($ millions)
Exhibit 21: Market scenario in APAC
Exhibit 22: GVHD treatment market in APAC 2016-2021 ($ millions)
Exhibit 23: Percentage distribution of transplants by organ in US (1988-2016)
Exhibit 24: Various major types of cancers managed by bone marrow transplant
Exhibit 25: Various off-label drugs used in the management of GVHD
Exhibit 26: Various symptoms and disorders associated with GVHD
Exhibit 27: Legal and ethical issues in countries
Exhibit 28: Inorganic growth strategies
Exhibit 29: Newer applications of bone marrow transplant
Exhibit 30: Competitive structure analysis of global GVHD treatment market 2016
Exhibit 31: Market penetration of various GVHD drugs manufacturers worldwide 2016
Exhibit 32: Strategic success factors of companies in global GVHD treatment market
Exhibit 33: Bristol-Myers Squibb: Key highlights
Exhibit 34: Bristol-Myers Squibb: Strength assessment
Exhibit 35: Bristol-Myers Squibb: Strategy assessment
Exhibit 36: Bristol-Myers Squibb: Opportunity assessment
Exhibit 37: F. Hoffmann-La Roche: Key highlights
Exhibit 38: F. Hoffmann-La Roche: Strength assessment
Exhibit 39: F. Hoffmann-La Roche: Strategy assessment
Exhibit 40: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 41: Novartis: Key highlights
Exhibit 42: Novartis: Strength assessment
Exhibit 43: Novartis: Strategy assessment
Exhibit 44: Novartis: Opportunity assessment
Exhibit 45: Pfizer: Key highlights
Exhibit 46: Pfizer: Strength assessment
Exhibit 47: Pfizer: Strategy assessment
Exhibit 48: Pfizer: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • Athersys
  • Caladrius
  • F Hoffmann-La Roche
  • Heron Therapeutics
  • Lupin
  • MORE
New Report Released: – Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021

The author of the report recognizes the following companies as the key players in the global graft vs host disease (GVHD) treatment market: Bristol-Myers Squibb, Novartis, Pfizer, and F. Hoffmann-La Roche.

Other Prominent Vendors in the market are: bbott, AbbVie, Allergan, Anterogen, Astellas Pharma, Athersys, Baxter, Caladrius, Cellular Biomedicine Group, Cipla, Eisai, Eli Lilly, GlaxoSmithKline, Glenmark, Helsinn Healthcare, Heron Therapeutics, Incyte Corporation, IPCA Laboratories, Kadmon Holdings, Lupin, Osiris Therapeutics, RedHill, Sanofi, Shire, Sun Pharmaceutical Industries, Takeda Pharmaceutical, and ViaCyte.

Commenting on the report, an analyst from the research team said: “One trend in the market is inorganic growth strategies. The inorganic growth strategies are expected to contribute the growth of GVHD treatment market as the market is completely based on off-label usage. These inorganic growth strategies include global merger and acquisition, partnerships and regional acquisition.”

According to the report, one driver in the market is increased prevalence of cancer. Globally, cancer is one of the life-threating diseases. As per National Institutes of Health (NIH), it is the second largest cause of death globally. As per National Cancer Institute, in the US alone, 1,685,210 new cancer cases and 595,690 cancer deaths were expected during 2016. The prevalence of this disease is growing at high rates and is expected to grow at higher rates in future too. Bone marrow transplant is widely preferred in various types of cancers.

Further, the report states that one challenge in the market is off-label use of drugs. GVHD is one of the clinical disorders arising due to tissue and organ transplantation. It is more commonly observed in allogeneic transplants where the tissue or organ from another donor is transplanted into an individual. There is no specific drug indicated for GVHD, and thus the current management of GVHD is based on the off-label use of various drug therapies. This off-label use of drugs is one of the biggest challenges in the global GVHD treatment market till date.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Bristol-Myers Squibb
  • Novartis
  • Pfizer
  • F Hoffmann-La Roche
  • bbott
  • AbbVie
  • Allergan
  • Anterogen
  • Astellas Pharma
  • Athersys
  • Baxter
  • Caladrius
  • Cellular Biomedicine Group
  • Cipla
  • Eisai
  • Eli Lilly
  • GlaxoSmithKline
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • Incyte Corporation
  • IPCA Laboratories
  • Kadmon Holdings
  • Lupin
  • Osiris Therapeutics
  • RedHill
  • Sanofi
  • Shire
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical
  • ViaCyte
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll